Keita Takeda

Dr. Keita Takeda

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in Medical Mycology
Verified
Journal Article
Closed access
KTKeita Takeda
Keita Takeda
JSJunko Suzuki
Junko Suzuki
AWAkira Watanabe
Akira Watanabe
TATeppei Arai
Teppei Arai
TKTomohiro Koiwa
Tomohiro Koiwa
KKKatsuhiko Kamei
Katsuhiko Kamei
The prevalence of azole-resistant Aspergillus fumigatus (ARAF) among chronic pulmonary aspergillosis (CPA) patients treated with azoles in Japan is unknown. The aim of this study was to determine the detection rate of ARAF in isolates from CPA patients who were treated with azoles for varying durations. The potential mechanism of acquiring resistance was examined by sequencing cyp51A and hmg1, two genes associated with ARAF. A. fumigatus isolates (n = 120) were collected from CPA patients (n = 104) between February 2012 and February 2019, at National Hospital Organization Tokyo National Hospital. The isolates were tested for susceptibility to the azole drugs itraconazole (ITCZ) and voriconazole (VRCZ). The detection rate of ARAF among all isolates was 8.3% (n = 10). Of the 10 resistant isolates, eight were ITCZ-resistant and five were VRCZ-resistant. Among 47 isolates obtained from 36 CPA patients who were treated with ITCZ (for an average of 256 days) and/or VRCZ (for an average of 29 days), the resistance rates were 17.0% and 10.6%, respectively. In addition, 46.2% of 13 isolates obtained from CPA patients with ongoing azole treatment at the time of antifungal therapy failure were resistant to azoles. Among the 10 ARAF isolates, a point mutation was detected in cyp51A in seven isolates and in hmg1 in two isolates. ARAF was detected at a high rate in CPA patients, particularly in those with ongoing long-term azole treatment, at the time of azole antifungal therapy failure.

26 June 2019 in Medical Mycology
Verified
Journal Article
Closed access
KTKeita Takeda
Keita Takeda
JSJunko Suzuki
Junko Suzuki
AWAkira Watanabe
Akira Watanabe
MMMei Matsuki
Mei Matsuki
KHKatsuyuki Higa
Katsuyuki Higa
KKKatsuhiko Kamei
Katsuhiko Kamei
Species of Aspergillus section Nigri are generally identified by molecular genetics approaches, whereas in clinical practice, they are classified as A. niger by their morphological characteristics. This study aimed to investigate whether the species of Aspergillus section Nigri isolated from the respiratory tract vary depending on clinical diagnosis. Forty-four Aspergillus section Nigri isolates isolated from the lower respiratory tracts of 43 patients were collected from February 2012 to January 2017 at the National Hospital Organization (NHO) Tokyo National Hospital. Species identification was carried out based on β-tubulin gene analysis. Drug susceptibility tests were performed according to the Clinical and Laboratory Standards Institute (CLSI) M38 3rd edition, and the clinical characteristics were retrospectively reviewed. A. welwitschiae was isolated most frequently, followed by A. tubingensis. More than half of the A. tubingensis isolates exhibited low susceptibility to azoles in contrast to only one A. welwitschiae isolate. Approximately three quarters of the patients from whom A. welwitschiae was isolated were diagnosed with colonization, whereas more than half the patients from whom A. tubingensis was isolated were diagnosed with chronic pulmonary aspergillosis (CPA). More attention needs to be given to the drug choice for patients with CPA with Aspergillus section Nigri infection because A. tubingensis, which was found to be frequently azole-resistant, was the most prevalent in these patients.

14 February 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
KSKyota Shinfuku
Kyota Shinfuku
JSJunko Suzuki
Junko Suzuki
KTKeita Takeda
Keita Takeda
MKMasahiro Kawashima
Masahiro Kawashima
YMYoshiteru Morio
Yoshiteru Morio
KKKatsuhiko Kamei
Katsuhiko Kamei
Pulmonary aspergillosis is the most common pulmonary fungal infection. However, Aspergillus is a ubiquitous, saprophytic fungus; it can be detected in respiratory specimens even in the absence of infection.

1 November 2020 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KTKeita Takeda
Keita Takeda
HNHideaki Nagai
Hideaki Nagai
MSMaho Suzukawa
Maho Suzukawa
RSRyo Sekiguchi
Ryo Sekiguchi
SAShunsuke Akashi
Shunsuke Akashi
STShigeto Tohma
Shigeto Tohma

16 November 2021 in Mycoses
Verified
Journal Article
Closed access
PDF file
KTKeita Takeda
Keita Takeda
JSJunko Suzuki
Junko Suzuki
Akira WatanabeAkira Watanabe
Akira Watanabe
RSRyo Sekiguchi
Ryo Sekiguchi
TSTomoya Sano
Tomoya Sano
KKKatsuhiko Kamei
Katsuhiko Kamei

16 February 2022 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
KTKeita Takeda
Keita Takeda
JSJunko Suzuki
Junko Suzuki
Akira WatanabeAkira Watanabe
Akira Watanabe
ONOsamu Narumoto
Osamu Narumoto
MKMasahiro Kawashima
Masahiro Kawashima
HMHirotoshi Matsui
Hirotoshi Matsui
Aspergillus antibody testing is key for the clinical diagnosis of chronic pulmonary aspergillosis (CPA) with high sensitivity. However, false-negative results in patients with CPA might be obtained, depending on the Aspergillus species.